Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
The study compared pembrolizumab plus axitinib and sunitinIB for advanced renal cell carcinoma. Median follow-up of 30.6 months showed continued clinical benefit. Results continue to support the first-line treatment as the standard of care.
